blindness from glp 1 Lipsitz, Ponterio & Comerford Glp1 blindness risk update :

Medicilon Case: Pharmacokinetic (PK) studies Pharmacokinetic properties of Compound A Compound A and Reference compound were evaluated for its pharmacokinetic (PK) properties in cynomolgus monkeys

July 17, 2025: EU Clears Ozempic for Heart Conditions, Even Though Reports of Side Effects Are Rising Drug regulators in the European Union have given doctors the all-clear to prescribe Ozempic to treat peripheral artery disease, a type of heart condition

Is it really beneficial for people living with all kinds of diabetes

Theyre overwhelmed Theyre overspending Theyre walking away from treatment that could change their lives You have the power to help them